Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SANOFI INDIA Dec-18 |
TEVA PHARMA Dec-13 |
SANOFI INDIA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 6,840 | 3,131 | - | |
Low | Rs | 4,630 | 2,720 | - | |
Sales per share (Unadj.) | Rs | 1,203.1 | 1,796.9 | - | |
Earnings per share (Unadj.) | Rs | 165.3 | 112.2 | - | |
Cash flow per share (Unadj.) | Rs | 209.9 | 257.5 | - | |
Dividends per share (Unadj.) | Rs | 84.00 | 98.26 | - | |
Dividend yield (eoy) | % | 1.5 | 3.4 | 43.6% | |
Book value per share (Unadj.) | Rs | 963.6 | 1,996.0 | - | |
Shares outstanding (eoy) | m | 23.03 | 848.00 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.8 | 1.6 | 292.8% | |
Avg P/E ratio | x | 34.7 | 26.1 | 133.2% | |
P/CF ratio (eoy) | x | 27.3 | 11.4 | 240.5% | |
Price / Book Value ratio | x | 6.0 | 1.5 | 406.1% | |
Dividend payout | % | 50.8 | 87.5 | 58.1% | |
Avg Mkt Cap | Rs m | 132,078 | 2,480,731 | 5.3% | |
No. of employees | `000 | 3.3 | 44.9 | 7.3% | |
Total wages/salary | Rs m | 4,068 | 0 | - | |
Avg. sales/employee | Rs Th | 8,393.8 | 33,902.6 | 24.8% | |
Avg. wages/employee | Rs Th | 1,232.4 | 0 | - | |
Avg. net profit/employee | Rs Th | 1,153.0 | 2,117.9 | 54.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 27,708 | 1,523,753 | 1.8% | |
Other income | Rs m | 897 | 0 | - | |
Total revenues | Rs m | 28,605 | 1,523,753 | 1.9% | |
Gross profit | Rs m | 6,235 | 417,281 | 1.5% | |
Depreciation | Rs m | 1,027 | 123,166 | 0.8% | |
Interest | Rs m | 7 | 29,929 | 0.0% | |
Profit before tax | Rs m | 6,098 | 264,185 | 2.3% | |
Minority Interest | Rs m | 0 | 1,200 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -173,423 | 0.0% | |
Tax | Rs m | 2,292 | -3,225 | -71.1% | |
Profit after tax | Rs m | 3,806 | 95,188 | 4.0% | |
Gross profit margin | % | 22.5 | 27.4 | 82.2% | |
Effective tax rate | % | 37.6 | -1.2 | -3,078.6% | |
Net profit margin | % | 13.7 | 6.2 | 219.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 15,922 | 1,029,137 | 1.5% | |
Current liabilities | Rs m | 6,235 | 897,495 | 0.7% | |
Net working cap to sales | % | 35.0 | 8.6 | 404.7% | |
Current ratio | x | 2.6 | 1.1 | 222.7% | |
Inventory Days | Days | 64 | 91 | 70.1% | |
Debtors Days | Days | 21 | 96 | 21.8% | |
Net fixed assets | Rs m | 7,539 | 497,691 | 1.5% | |
Share capital | Rs m | 230 | 3,751 | 6.1% | |
Net worth | Rs m | 22,192 | 1,692,601 | 1.3% | |
Long term debt | Rs m | 0 | 779,129 | 0.0% | |
Total assets | Rs m | 29,839 | 3,482,264 | 0.9% | |
Interest coverage | x | 872.1 | 9.8 | 8,874.9% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.4 | 212.2% | |
Return on assets | % | 12.8 | 3.6 | 355.7% | |
Return on equity | % | 17.2 | 5.6 | 305.0% | |
Return on capital | % | 27.5 | 4.9 | 557.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,739 | 242,807 | 1.5% | |
From Investments | Rs m | -731 | -86,036 | 0.8% | |
From Financial Activity | Rs m | -1,972 | -291,264 | 0.7% | |
Net Cashflow | Rs m | 1,036 | -134,493 | -0.8% |
Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare SANOFI INDIA With: VENUS REMEDIES DR. REDDYS LAB PIRAMAL ENTERPRISES SUVEN LIFE SCIENCES DR. DATSONS LABS
Indian share markets ended on a positive note yesterday, helped by gains in metals and banking stocks.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
More